Eagle Pharmaceuticals, Inc. Gross Profit
Eagle Pharmaceuticals, Inc. reported Gross Profit of $36.67 million for the 3-month period ending 2019-12-31, per its 10-K filed 2020-03-02.
Discontinued › Income Statement
us-gaap:GrossProfit · last filed 2020-03-02
- Eagle Pharmaceuticals, Inc. gross profit for the quarter ending 2019-12-31 was $36.67M, a 2.21% decline year-over-year.
- Eagle Pharmaceuticals, Inc. gross profit for the quarter ending 2019-09-30 was $26.23M, a 31.61% decline year-over-year.
- Eagle Pharmaceuticals, Inc. gross profit for the quarter ending 2019-06-30 was $35.42M, a 13.06% decline year-over-year.
- Eagle Pharmaceuticals, Inc. gross profit for the quarter ending 2019-03-31 was $36.69M, a 5.36% increase year-over-year.
- Eagle Pharmaceuticals, Inc. gross profit for fiscal 2019 was $135.00M, a 10.83% decline from fiscal 2018.
- Eagle Pharmaceuticals, Inc. gross profit for fiscal 2018 was $151.40M.
| Period end | Gross Profit 3 month | Gross Profit 6 month | Gross Profit 9 month | Gross Profit 12 month |
|---|---|---|---|---|
| 2019-12-31 | $36.67M 10-K · filed 2020-03-02 | $62.89M derived: sum of 2 quarters · filed 2020-03-02 | $98.31M derived: sum of 3 quarters · filed 2020-03-02 | $135.00M 10-K · filed 2020-03-02 |
| 2019-09-30 | $26.23M 10-K · filed 2020-03-02 | $61.64M derived: sum of 2 quarters · filed 2020-03-02 | $98.33M derived: sum of 3 quarters · filed 2020-03-02 | $135.82M derived: sum of 4 quarters · filed 2020-03-02 |
| 2019-06-30 | $35.42M 10-K · filed 2020-03-02 | $72.10M derived: sum of 2 quarters · filed 2020-03-02 | $109.60M derived: sum of 3 quarters · filed 2020-03-02 | $147.94M derived: sum of 4 quarters · filed 2020-03-02 |
| 2019-03-31 | $36.69M 10-K · filed 2020-03-02 | $74.18M derived: sum of 2 quarters · filed 2020-03-02 | $112.53M derived: sum of 3 quarters · filed 2020-03-02 | $153.26M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-12-31 | $37.49M 10-K · filed 2020-03-02 | $75.84M derived: sum of 2 quarters · filed 2020-03-02 | $116.58M derived: sum of 3 quarters · filed 2020-03-02 | $151.40M 10-K · filed 2020-03-02 |
| 2018-09-30 | $38.35M 10-K · filed 2020-03-02 | $79.08M derived: sum of 2 quarters · filed 2020-03-02 | $113.90M derived: sum of 3 quarters · filed 2020-03-02 | |
| 2018-06-30 | $40.74M 10-K · filed 2020-03-02 | $75.56M derived: sum of 2 quarters · filed 2020-03-02 | ||
| 2018-03-31 | $34.82M 10-K · filed 2020-03-02 |